Poplar-type Propolis Dry Extract ESIT12 : Immunomodulation Efficacy Study

Inclusion Criteria: * inactive or minimally active according to the IPAQ short form questionnaire * BMI 18,5-29,9 Exclusion Criteria: * Pregnant women, breastfeeding women, women positive at Beta-HCG serology test and who hope to become pregnant * Allergy to beehive products and known allergy (general) * Cystic fibrosis * Congenital or acquired immunodeficiency syndrome and disease * History of asthma (within prior 24 months) or chronic respiratory disease * Subjects who underwent medical treatment for COVID-19 within last 3 months * History of immune system disorder or auto-immune disorder * History of treated diabetes or treated hypertension * Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, and malignancies * Cancers * Those considered unsuitable for the participation by the physician * No vaccination within 12 weeks prior to enrolling in the study * No antibiotics within 12 weeks prior to enrolling in the study * No anti-inflammatory drugs within 4 weeks prior to enrolling in the study * No steroids within 12 weeks prior to enrolling in the study * No immunological drugs within 4 weeks prior to enrolling in the study * No food/dietary supplements within 4 weeks prior to enrolling in the study * No current or recent participation in another clinical trial (within 30 days prior to screening)